RECRUITING

Immunometabolic Mechanisms of Blood Flow Restriction (BFR) Training After Anterior Cruciate Ligament Reconstruction

Talk to us

Conditions

Anterior Cruciate Ligament ReconstructionAirBand

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a crossover phase 4 study to evaluate the impact of blood flow restriction on immunometabolism and gene expression in immune cells in individuals undergoing rehabilitation from anterior cruciate ligament reconstruction.

Official Title

Immunometabolic Mechanisms of Blood Flow Restriction Training After Anterior Cruciate Ligament Reconstruction

Quick Facts

Study Start:2023-02-16
Study Completion:2025-04-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05012982

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 60 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Provision of signed and dated informed consent form
  2. 2. Stated willingness to comply with all study procedures and availability for two study visits at least 1 week apart
  3. 3. All genders, between 18 and 60 years of age
  4. 4. In good general health without any underlying medical conditions or prior injury that would place the subject at risk of further injury/illness by participating in the study
  1. 1. Serious medical conditions including cardiovascular, metabolic (diabetes), rheumatologic, pulmonary, or musculoskeletal.
  2. 2. Multiple ligament ruptures or trauma
  3. 3. Rheumatoid arthritis or other significant comorbidities
  4. 4. Lower extremity vascular pathology, including history of deep vein thrombosis
  5. 5. Those with a history of sickle cell trait or disease
  6. 6. Use of anticoagulant medications
  7. 7. Pregnancy
  8. 8. Treatment with another investigational drug or other intervention within one month of Study Day 1
  9. 9. Current smoker or tobacco use within 3 months of Study Day 1
  10. 10. Febrile illness within 2 weeks of Study Day 1

Contacts and Locations

Study Contact

Rachel Perry, PhD
CONTACT
203-506-5179
rachel.perry@yale.edu
Andin Fosam, BS
CONTACT
609-578-7713
andin.fosam@yale.edu

Principal Investigator

Rachel Perry, PhD
PRINCIPAL_INVESTIGATOR
Yale University

Study Locations (Sites)

Yale New Haven Hospital
Milford, Connecticut, 06461
United States

Collaborators and Investigators

Sponsor: Yale University

  • Rachel Perry, PhD, PRINCIPAL_INVESTIGATOR, Yale University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-02-16
Study Completion Date2025-04-01

Study Record Updates

Study Start Date2023-02-16
Study Completion Date2025-04-01

Terms related to this study

Keywords Provided by Researchers

  • AirBand

Additional Relevant MeSH Terms

  • Anterior Cruciate Ligament Reconstruction